{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:44:48Z","timestamp":1785681888951,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bariatric surgery and obesity increase VTE risk. While VTE incidence after bariatric surgery is low, it impacts morbidity and 30-day mortality. The lack of consensus on the optimal thromboprophylaxis has driven research into alternatives like DOACs. The objective of this study is to determine the efficacy and safety of rivaroxaban as thromboprophylaxis after bariatric surgery and the most effective thromboprophylaxis strategy. Findings from the nine included studies show that rivaroxaban is as effective as controls for DVT\/PE prevention, with no PMVT cases. The incidence of minor and major bleeding requiring transfusion are more common with rivaroxaban however the meta-analysis does not consider this as significant evidence against its use. In the subgroup analysis, no significant differences are observed between long- and short-course rivaroxaban regimens across all primary outcomes, though shorter courses showed fewer bleeding complications.<\/jats:p>","DOI":"10.1007\/s11695-026-08774-3","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:02:34Z","timestamp":1782867754000},"page":"4421-4440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review and Meta-Analysis on the Use of Rivaroxaban as Thromboprophylaxis Following Bariatric Surgery"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-2693","authenticated-orcid":false,"given":"Sarah","family":"Catania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-6885","authenticated-orcid":false,"given":"Clifford","family":"Caruana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"2","key":"8774_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.soard.2021.10.023","volume":"18","author":"A Aminian","year":"2022","unstructured":"Aminian A, Vosburg RW, Altieri MS, et al. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery. Surg Obes Relat Dis. 2022;18(2):165\u201374. https:\/\/doi.org\/10.1016\/j.soard.2021.10.023.","journal-title":"Surg Obes Relat Dis"},{"issue":"8","key":"8774_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/EJA.0000000000002000","volume":"41","author":"JI Arcelus","year":"2024","unstructured":"Arcelus JI, Gouin-Thibault I, Samama CM. European guidelines on peri-operative venous thromboembolism prophylaxis: first update: chapter 10: surgery in the obese patient. Eur J Anaesthesiol. 2024;41(8):607. https:\/\/doi.org\/10.1097\/EJA.0000000000002000.","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"8774_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40256-020-00434-w","volume":"21","author":"V Ashton","year":"2021","unstructured":"Ashton V, Mudarris L, Moore KT. The pharmacology, efficacy, and safety of rivaroxaban in obese patient populations. Am J Cardiovasc Drugs. 2021;21(3):283\u201397. https:\/\/doi.org\/10.1007\/s40256-020-00434-w.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"8774_CR4","volume":"5","author":"B Bayat","year":"2022","unstructured":"Bayat B, Obney JR, Goudarzi H, et al. The influence of enoxaparin or rivaroxaban for venous thromboembolism in morbidly obese patients undergoing bariatric surgery. Med Clin Pract. 2022;5(4):100334.","journal-title":"Med Clin Pract"},{"issue":"3","key":"8774_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.21608\/EJSUR.2024.279555.1034","volume":"43","author":"MA Eissa","year":"2024","unstructured":"Eissa MA, Elmahdy TM, Elgarf S, et al. Oral rivaroxaban for postoperative prophylaxis of venous thromboembolism after sleeve gastrectomy in patients with morbid obesity, is it safe: a prospective randomized clinical trial. Egypt J Surg. 2024;43(3):1083\u20139.","journal-title":"Egypt J Surg"},{"issue":"3","key":"8774_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.21608\/EJSUR.2024.275171.1016","volume":"43","author":"MH Elemawy","year":"2024","unstructured":"Elemawy MH, Abo-Ryia MH, Ismail TA, et al. Assessment of rivaroxaban as venous thromboembolism prophylaxis after gastric bypass surgery. Egypt J Surg. 2024;43(3):1049\u201353.","journal-title":"Egypt J Surg"},{"key":"8774_CR7","unstructured":"Ezz RSM, Rizk MAEM, Khalil MMH et al. A Prospective study comparing the effect of rivaroxaban vs. enoxaparin given as a prophylaxis for deep venous thrombosis in patients undergoing bariatric surgery. Kasr El-Aini J Surg. 2019;20(2):37."},{"issue":"4","key":"8774_CR8","first-page":"1233","volume":"40","author":"AM Farrag","year":"2021","unstructured":"Farrag AM, Fouly MG, Elrifaie AY, et al. Is rivaroxaban a safe and effective oral alternative to low-molecular-weight heparin in prophylaxis of portomesenteric and lower-limb deep-vein thrombosis after sleeve gastrectomy? Egypt J Surg. 2021;40(4):1233\u201341.","journal-title":"Egypt J Surg"},{"issue":"10","key":"8774_CR9","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1007\/s11999-013-3049-9","volume":"471","author":"RJ Friedman","year":"2013","unstructured":"Friedman RJ, Hess S, Berkowitz SD, et al. Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res. 2013;471(10):3358\u201366. https:\/\/doi.org\/10.1007\/s11999-013-3049-9.","journal-title":"Clin Orthop Relat Res"},{"key":"8774_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/CPAA.S61131","volume":"6","author":"C Frost","year":"2014","unstructured":"Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol: Adv Appl. 2014;6:179\u201387. https:\/\/doi.org\/10.2147\/CPAA.S61131.","journal-title":"Clin Pharmacol: Adv Appl"},{"issue":"5","key":"8774_CR11","doi-asserted-by":"publisher","first-page":"e2315241","DOI":"10.1001\/jamanetworkopen.2023.15241","volume":"6","author":"D Kr\u00f6ll","year":"2023","unstructured":"Kr\u00f6ll D, Nett PC, Rommers N, et al. Efficacy and safety of rivaroxaban for postoperative thromboprophylaxis in patients after bariatric surgery: a randomized clinical trial. JAMA Netw Open. 2023;6(5):e2315241. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15241.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"8774_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.surg.2021.03.005","volume":"170","author":"L Luo","year":"2021","unstructured":"Luo L, Li H, Wu Y, et al. Portal venous system thrombosis after bariatric surgery: a systematic review and meta-analysis. Surgery. 2021;170(2):363\u201372. https:\/\/doi.org\/10.1016\/j.surg.2021.03.005.","journal-title":"Surgery"},{"issue":"8","key":"8774_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874\u201382. https:\/\/doi.org\/10.1111\/jth.15358.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"8774_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"issue":"9","key":"8774_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.amjmed.2017.05.011","volume":"130","author":"KT Moore","year":"2017","unstructured":"Moore KT, Kr\u00f6ll D. Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. Am J Med. 2017;130(9):1024\u201332. https:\/\/doi.org\/10.1016\/j.amjmed.2017.05.011.","journal-title":"Am J Med"},{"issue":"9","key":"8774_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1308\/rcsann.2020.0209","volume":"102","author":"JI Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez JI, Kobus V, T\u00e9llez I, et al. Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portomesenteric venous thrombosis. Ann R Coll Surg Engl. 2020;102(9):712\u20136. https:\/\/doi.org\/10.1308\/rcsann.2020.0209.","journal-title":"Ann R Coll Surg Engl"},{"key":"8774_CR17","doi-asserted-by":"publisher","first-page":"762310","DOI":"10.1155\/2013\/762310","volume":"2013","author":"RD Russell","year":"2013","unstructured":"Russell RD, Hotchkiss WR, Knight JR, et al. The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. Thrombosis. 2013;2013:762310. https:\/\/doi.org\/10.1155\/2013\/762310.","journal-title":"Thrombosis"},{"issue":"4","key":"8774_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11695-023-06471-z","volume":"33","author":"DE Swartz","year":"2023","unstructured":"Swartz DE, Hood L, Swartz DR, et al. 30-Day Post-discharge prophylaxis with rivaroxaban prevents porto-mesenteric venous thrombosis following laparoscopic sleeve gastrectomy. Obes Surg. 2023;33(4):1026\u201331. https:\/\/doi.org\/10.1007\/s11695-023-06471-z.","journal-title":"Obes Surg"},{"issue":"5","key":"8774_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5604\/01.3001.0016.2729","volume":"95","author":"V Tyselskyi","year":"2023","unstructured":"Tyselskyi V, Tryliskyy Y, Poylin V, et al. Prolonged thromboprophylaxis with rivaroxaban after bariatric interventions: a single-centre experience. Pol J Surg. 2023;95(5):76\u201381.","journal-title":"Pol J Surg"},{"issue":"6","key":"8774_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jrsm.1460","volume":"11","author":"F Weber","year":"2020","unstructured":"Weber F, Knapp G, Ickstadt K, et al. Zero-cell corrections in random-effects meta-analyses. Res Synth Methods. 2020;11(6):913\u20139. https:\/\/doi.org\/10.1002\/jrsm.1460.","journal-title":"Res Synth Methods"},{"issue":"1","key":"8774_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-024-05087-y","volume":"19","author":"L Zhu","year":"2024","unstructured":"Zhu L, Zhu B, Bing P, et al. Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: A meta-analysis of randomized controlled trials. J Orthop Surg Res. 2024;19(1):609. https:\/\/doi.org\/10.1186\/s13018-024-05087-y.","journal-title":"J Orthop Surg Res"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08774-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08774-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08774-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T13:58:24Z","timestamp":1785679104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08774-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8774"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08774-3","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}